Lung Diseases  >>  Synagis (palivizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Synagis (palivizumab) / SOBI
NCT00316264: Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Completed
2
260
RoW
Motavizumab, palivizumab, Palivizumab, motavizumab, Motavizumab
MedImmune LLC
Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or, Premature With Gestational Age <=35 Weeks and <=6 Months of Age
02/07
02/07

Download Options